The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effects of establishing a multidisciplinary pancreatic cancer clinic on time-to-treatment.
 
Raj Vaghjiani
No Relationships to Disclose
 
Joy Sarkar
No Relationships to Disclose
 
Zachary Stiles
No Relationships to Disclose
 
Jennifer Pangelinan
No Relationships to Disclose
 
Renuka V. Iyer
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Bayer; Eisai; Exelixis; Ipsen; Lexicon; Merck; Novartis; QED therapeutics; Sandoz; Sun pharma; Tersera
Research Funding - Cleveland BioLabs (Inst); Genentech/Roche (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Benjamin F. Calvo
No Relationships to Disclose
 
Moshim Kukar
No Relationships to Disclose
 
Steven N. Hochwald
No Relationships to Disclose
 
Nadia Karen Malik
No Relationships to Disclose
 
Christos Fountzilas
Research Funding - Aravive (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Corcept Therapeutics (Inst); Dragonfly Therapeutics (Inst); ERYTECH Pharma (Inst); Incyte (Inst); Ipsen (Inst); Kadmon (Inst); Kinex (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst); Syndax (Inst); Taiho Oncology (Inst)
 
Sylvia Vania Alarcon Velasco
No Relationships to Disclose
 
Leonid Cherkassky
No Relationships to Disclose